Want to see HK:2493 full AI Analyst Report?
2493 Stock Chart & Stats
HK$20.66
-HK$0.10(-0.48%)
―
--
Day’s Range― - ―
52-Week RangeHK$20.16 - HK$31.46
Previous CloseN/A
VolumeN/A
Average Volume (3M)321.97K
Market Cap
HK$17.84B
Enterprise ValueHK$11.83K
Total Cash (Recent Filing)HK$2.29B
Total Debt (Recent Filing)HK$3.35B
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding47,130,200
10 Day Avg. Volume248,160
30 Day Avg. Volume321,966
Financial Highlights & Ratios
PEG Ratio1.42
Price to Book (P/B)27.25
Price to Sales (P/S)14.37
P/FCF Ratio-21.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth of 17.3% indicates improving commercial traction and broader adoption of the company’s marketed or partnered products. If sustained, a larger revenue base can improve operating leverage, support pipeline investment, and strengthen the platform’s ability to fund future expansion.
Gross MarginA gross margin near 74.5% demonstrates attractive product-level economics for the current revenue base. This provides meaningful room to absorb research, development, regulatory, and commercial costs, while creating potential for stronger profitability if operating expenses become more disciplined.
Narrowing LossesMaterially narrower losses than in 2023–2024 suggest the business is moving in the right direction operationally, even though it remains far from break-even. Continued improvement could reduce the scale of future funding needs and increase the value of revenue growth over time.
Bears Say
Severe Operating LossesExtremely negative EBIT and net margins show that current revenue is insufficient to cover the company’s operating cost base. Persistent losses can delay the path to self-sustaining profitability, constrain reinvestment choices, and make future growth dependent on continued external financing.
Heavy Cash BurnLarge operating and free-cash-flow outflows indicate that the company is still consuming substantial cash to run the business and fund investment. Without a sustained cash-generation inflection, ongoing development and commercialization activities may require repeated external funding.
Elevated LeverageDebt-to-equity of about 3.84x leaves the balance sheet highly leveraged relative to positive equity of approximately 873.3m. This reduces financial flexibility, increases sensitivity to prolonged losses or tighter funding conditions, and may limit the company’s ability to invest freely in growth.
Mabwell (Shanghai) Bioscience Co., Ltd. Class H News
2493 FAQ
What was Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s price range in the past 12 months?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H lowest stock price was HK$20.16 and its highest was HK$31.46 in the past 12 months.
What is Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s market cap?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s market cap is HK$17.84B.
When is Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s upcoming earnings report date?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s upcoming earnings report date is Oct 22, 2026 which is in 44 days.
How were Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s earnings last quarter?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H released its earnings results on Apr 23, 2026. The company reported -HK$0.685 earnings per share for the quarter.
Is Mabwell (Shanghai) Bioscience Co., Ltd. Class H overvalued?
According to Wall Street analysts Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s price is currently Undervalued.
Does Mabwell (Shanghai) Bioscience Co., Ltd. Class H pay dividends?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H does not currently pay dividends.
What is Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s EPS estimate?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabwell (Shanghai) Bioscience Co., Ltd. Class H have?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H has 47,130,200 shares outstanding.
What happened to Mabwell (Shanghai) Bioscience Co., Ltd. Class H’s price movement after its last earnings report?
Mabwell (Shanghai) Bioscience Co., Ltd. Class H reported an EPS of -HK$0.685 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Mabwell (Shanghai) Bioscience Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2493
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mabwell (Shanghai) Bioscience Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.
Mabwell (Shanghai) Bioscience Co., Ltd. Class H (2493) Earnings & Revenues
Technical Analysis
Innovent Biologics
―
Akeso, Inc.
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―